New Drug Approvals Archive - November 2012
New Indication Approved: November 2, 2012
Xeljanz (tofacitinib) Tablets
Date of Approval: November 6, 2012
Xeljanz (tofacitinib) is an oral Janus kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
New Indication Approved: November 16, 2012
Flucelvax (influenza virus vaccine)
Date of Approval: November 20, 2012
Flucelvax (influenza virus vaccine) is an inactivated vaccine indicated for active immunization for the prevention of influenza.
Cometriq (cabozantinib) Capsules
Date of Approval: November 29, 2012
Cometriq (cabozantinib) is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.